ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer

Fang, Kun*; Xu, Zhengjie; Jiang, Suxiao; Yan, Changsheng; Tang, Desheng; Huang, Yan哈尔滨医科大学; 1
Frontiers in Immunology2022-11-25DOI: 10.3389/fimmu.2022.985861
1被引10阅读
引用收藏
分享

摘要

ObjectiveFerroptosis is an iron-dependent type of regulated cell death triggered by the toxic buildup of lipid peroxides on cell membranes. Nonetheless, the implication of ferroptosis in triple-negative breast cancer (TNBC), which is the most aggressive subtype of breast carcinoma, remains unexplored. MethodsThree TNBC cohorts-TCGA-TNBC, GSE58812, and METABRIC-were adopted. Consensus molecular subtyping on prognostic ferroptosis-related genes was implemented across TNBC. Ferroptosis classification-relevant genes were selected through weighted co-expression network analysis (WGCNA), and a ferroptosis-relevant scoring system was proposed through the LASSO approach. Prognostic and immunological traits, transcriptional and post-transcriptional modulation, therapeutic response, and prediction of potential small-molecule agents were conducted. ResultsThree disparate ferroptosis patterns were identified across TNBC, with prognostic and immunological traits in each pattern. The ferroptosis-relevant scoring system was proposed, with poorer overall survival in high-risk patients. This risk score was strongly linked to transcriptional and post-transcriptional mechanisms. The high-risk group had a higher response to anti-PD-1 blockade or sunitinib, and the low-risk group had higher sensitivity to cisplatin. High relationships of risk score with immunological features were observed across pan-cancer. Two Cancer Therapeutics Response Portal (CTRP)-derived agents (SNX-2112 and brefeldin A) and PRISM-derived agents (MEK162, PD-0325901, PD-318088, Ro-4987655, and SAR131675) were predicted, which were intended for high-risk patients. ConclusionAltogether, our findings unveil prognostic, immunological, and pharmacogenomic features of ferroptosis in TNBC, highlighting the potential clinical utility of ferroptosis in TNBC therapy.

学科与关键词

关键词
triple-negative breast cancerferroptosisprognosisimmunological featureimmunotherapy
相关
加载中…
  • Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
    Wang, Yaru; Sun, Yue; Wang, Feiran; Wang, Hongyi; Hu, Jing*Biomedicine and Pharmacotherapy, 2023, 169: 115866.
  • Combination Analysis of Ferroptosis and Immune Status Predicts Patients Survival in Breast Invasive Ductal Carcinoma
    Yang, Yang; Luo, Dankun; Gao, Wenqi; Wang, Qiang; Yao, Wenchao; Xue, Dongbo*; Ma, Biao*Biomolecules, 2023, 13(1): 147.
  • Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression
    Sui, Shiyao; Xu, Shouping*; Pang, Da*Pharmacology and Therapeutics, 2022, 232: 107992.被引 51
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-11-25
卷期
第 13 卷
页码
985861
DOI
10.3389/fimmu.2022.985861
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Ningxia Hui Autonomous Region Natural Science Foundation Project [2022AAC03748, 2021AAC03523]; Basic research project of Yinchuan Maternal and Child Health Hospital [2022NYFYCX05]

作者

  • F

    Fang, Kun (通讯) (第一作者)

  • X

    Xu, Zhengjie

查看全部 6 位作者收起作者
  • J

    Jiang, Suxiao

  • Y

    Yan, Changsheng

    1 · harbin med univ

  • T

    Tang, Desheng

    1 · harbin med univ

  • H

    Huang, Yan

    ningxia med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417